Alkermes Plc CFO James M. Frates Sells 16,000 Shares (ALKS)
Alkermes Plc (NASDAQ:ALKS) CFO James M. Frates unloaded 16,000 shares of the stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $45.08, for a total transaction of $721,280.00. Following the completion of the sale, the chief financial officer now directly owns 44,225 shares in the company, valued at approximately $1,993,663. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Alkermes Plc (NASDAQ:ALKS) traded up 0.67% on Wednesday, hitting $45.37. 490,336 shares of the company’s stock traded hands. Alkermes Plc has a one year low of $29.36 and a one year high of $54.25. The stock’s 50-day moving average is $44.69 and its 200-day moving average is $46.41. The company’s market cap is $6.616 billion.
Alkermes Plc (NASDAQ:ALKS) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by $0.03. The company had revenue of $153.40 million for the quarter, compared to the consensus estimate of $146.91 million. During the same quarter in the previous year, the company posted $0.30 earnings per share. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. On average, analysts predict that Alkermes Plc will post $0.27 earnings per share for the current fiscal year.
A number of research firms have recently commented on ALKS. Analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Wednesday, August 6th. They now have a $45.00 price target on the stock. Separately, analysts at Credit Suisse cut their price target on shares of Alkermes Plc from $57.00 to $56.00 in a research note on Friday, August 1st. Finally, analysts at Mizuho cut their price target on shares of Alkermes Plc from $61.00 to $59.00 in a research note on Thursday, July 31st. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $48.50.
Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.
Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.